Related Experiment Videos
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
Infection and Immunity
|August 23, 2005
Summary
Botulinum neurotoxins (BoNTs) show significant sequence variability within serotypes, impacting antibody effectiveness. Developing diagnostics and therapeutics requires accounting for this subtype variation for optimal immune recognition and neutralization.
Area of Science:
- Microbiology
- Immunology
- Biochemistry
Background:
- Botulinum neurotoxins (BoNTs) are Category A biothreat agents requiring effective countermeasures.
- Existing vaccines and antibody therapies must address extensive BoNT sequence variability across and within serotypes.
Purpose of the Study:
- To analyze BoNT sequence variability within serotypes.
- To determine the impact of BoNT subtype sequence differences on monoclonal antibody (MAb) binding and neutralization capacity.
Main Methods:
- Analysis of 49 complete published BoNT sequences to assess intra-serotype variability.
- Evaluation of binding affinity and in vivo neutralization of six BoNT/A MAbs against BoNT/A1 and BoNT/A2 subtypes.
Main Results:
- BoNTs exhibit significant sequence variability within serotypes (2.6–31.6%).
- Three of six BoNT/A MAbs showed 500- to >1,000-fold reduced binding affinity to BoNT/A2 compared to BoNT/A1.
- MAb neutralization capacity correlated with binding; MAbs ineffective against A2 showed minimal neutralization, while broadly binding MAbs neutralized both subtypes.
Conclusions:
- Intra-serotype sequence variability in BoNTs significantly impacts MAb recognition and neutralization.
- Diagnostic and therapeutic antibody development must consider BoNT subtype sequence variability for efficacy.